title: A clinical study of 57 children with fetal anticonvulsant syndromes.
abstract: BACKGROUND
  Anticonvulsants taken in pregnancy are associated with an increased risk of malformations and developmental delay in the children. To evaluate the pattern of abnormalities associated with prenatal anticonvulsant exposure further, we undertook a clinical study of 57 children with fetal anticonvulsant syndromes.
  
  
  METHODS
  Fifty two children were ascertained through the Fetal Anticonvulsant Syndrome Association and five were referred to the Aberdeen Medical Genetics Service. Pregnancy and medical history were obtained through a standardised questionnaire and interview and the children were examined.
  
  
  RESULTS
  Thirty four (60%) were exposed in utero to valproate alone, four (7%) to carbamazepine alone, four (7%) to phenytoin alone, and 15 (26%) to more than one anticonvulsant. Forty six (81%) reported behavioural problems, 22 (39%) with hyperactivity or poor concentration of whom four (7%) had a diagnosis of attention deficit and hyperactivity disorder. Thirty four (60%) reported two or more autistic features, of whom four had a diagnosis of autism and two of Asperger's syndrome. Forty four (77%) had learning difficulties, 46 (81%) had speech delay, 34 (60%) had gross motor delay, and 24 (42%) had fine motor delay. Nineteen (33%) had glue ear and 40 (70%) had joint laxity involving all sizes of joints. Of 46 who had formal ophthalmic evaluation, 16 (34%) had myopia.
  
  
  CONCLUSIONS
  Speech delay, joint laxity, glue ear, and myopia are common in the fetal anticonvulsant syndromes and autistic features and hyperactivity form part of the behavioural phenotype.
authors.affiliation: Department of Medical Genetics, Medical School, Foresterhill, Aberdeen UK.
authors.forename: S J
authors.initials: SJ
authors.lastname: Moore
authors.forename: P
authors.initials: P
authors.lastname: Turnpenny
authors.forename: A
authors.initials: A
authors.lastname: Quinn
authors.forename: S
authors.initials: S
authors.lastname: Glover
authors.forename: D J
authors.initials: DJ
authors.lastname: Lloyd
authors.forename: T
authors.initials: T
authors.lastname: Montgomery
authors.forename: J C
authors.initials: JC
authors.lastname: Dean
mesh_terms: D000014:Abnormalities, Drug-Induced; D000293:Adolescent; D000927:Anticonvulsants / Q000009:adverse effects* / Q000627:therapeutic use; D002220:Carbamazepine / Q000009:adverse effects / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D004827:Epilepsy / Q000188:drug therapy; D005260:Female; D005315:Fetal Diseases / Q000139:chemically induced*; D006801:Humans; D007223:Infant; D008297:Male; D010641:Phenotype; D010672:Phenytoin / Q000009:adverse effects / Q000627:therapeutic use; D011247:Pregnancy; D013577:Syndrome; D014635:Valproic Acid / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D000927:Anticonvulsants; D002220:Carbamazepine; D014635:Valproic Acid; D010672:Phenytoin